The great impostor: Lues maligna in an HIV-infected male

Alfredo J Mena Lora1, Marylee Braniecki1, Ayman Nasir2 and Maximo Brito1

Abstract
Lues maligna is a rare severe cutaneous manifestation of secondary syphilis. It is also known as malignant syphilis and ulceronodular syphilis. We report a case of a 58-year-old HIV-infected male who presented with diffuse, pruritic, non-tender, maculo-papular skin lesions, ulcerated nodules and plaques surrounded by an erythematous base. The disseminated skin lesions were at various stages and were located on his back, chest, arms and testicles. Patient had been receiving antiretroviral therapy. Laboratory studies had demonstrated CD4 lymphocyte count of 463 cells/mm3 and an undetectable HIV viral load. Workup revealed a rapid plasma reagin of 1:256 dilutions and the skin biopsy findings were compatible with syphilis. The skin lesions resolved with intramuscular penicillin. We herein describe a rare case of lues maligna in an HIV-infected patient with a preserved immune function and viral suppression. Such skin lesions can mimic fungal or mycobacterial infections and can pose a diagnostic challenge. Even in the modern era, syphilis remains the great impostor. Clinicians must be able to recognize this condition based on clinical characteristics and risk factors to diagnose and treat this condition promptly.

Keywords
Infectious diseases, dermatology

Introduction
Lues maligna (LM) is a rare dermatologic manifestation of Treponema pallidum. We describe a male infected with human immunodeficiency virus (HIV) who presented with disseminated papulopustules and ulcerated nodules at various stages. The clinical presentation of this case can be a diagnostic challenge and can mimic other diseases such as fungal, mycobacterial and herpetic infections, as well as, pityriasis lichenoides et varioliformis acuta.1 Clinicians must be aware of this rare cutaneous manifestation of a common sexually transmitted illness (STI) in the differential diagnosis, especially in those populations who are at risk.

Case report
A 58-year-old HIV-infected man who has sex with men (MSM) presented with a 2-week history of diffuse, non-tender, pruritic skin lesions at different stages. The lesions initially appeared as red macules on his chest and arms, and evolved into raised papular, darkened violaceous lesions surrounded by an erythematous base. More lesions later developed on his back, legs, feet and testicles (see Figure 1). The patient had a medical history of HIV and prior STIs. He was diagnosed in 1987 and has been compliant with his antiretroviral therapy (ART) for the past 15 years. His ART medications included emtricitabine, rilpivirine and tenofovir in a once-daily combination pill. Blood tests revealed a CD4 count at 463 cells/mm3 and the HIV viral load was undetectable.

Physical examination revealed a large 4 cm crusted plaque on his right abdomen, plus scattered annular dime-sized crusted papules on chest, back, arms, legs, feet and testicles. Laboratory testing reported normal complete blood counts,
liver function tests and chemistry panel. Chest radiography was unremarkable. Urine Blastomyces Ag was negative. The quantitative rapid plasma reagin (RPR) was reported positive with a 1:256 dilution. The patient received one dose of intramuscular penicillin. A skin biopsy was performed 5 days after treatment. Microscopic examination showed dermal lymphoplasmacytic infiltrates with overlying cutaneous ulceration suggestive of syphilis (see Figure 2). Special stains including periodic acid–Schiff (PAS), acid-fast bacilli (AFB) and Steiner stains did not reveal fungi, mycobacteria or spirochetes, respectively. The patient was asymptomatic 3 weeks after treatment.

Discussion

LM was first described in 1859 by Bazin. Huslund and Neisser independently classified LM as a rare and severe variant of secondary syphilis in 1896. Prior to the advent of HIV, LM had an estimated incidence of 0.12%–0.36% and was mostly described in patients with severe malnourishment or chronic alcoholism. Only 14 cases were reported in the literature prior to 1988. The HIV epidemic coincided with a rise in reported syphilis cases in the United States affecting the same at-risk populations. HIV-positive patients are more than 60 times more likely to develop LM than HIV-negative patients. Despite this rise, LM remains rare. To our knowledge, less than 40 cases of HIV-related LM have been reported in the literature. Rare cases in immunocompetent or HIV-positive individuals with adequate T cells have been described, including patients with poorly controlled diabetes. Most HIV-related cases occur in poorly controlled patients with CD4 counts between 100 and 350. Immune reconstitution inflammatory syndrome (IRIS) seems to increase the risk of LM developing in HIV-infected patients.

Various terms have been used to describe LM, including malignant syphilis, syphilis maligna praecox or ulceronodular syphilis. The hallmark of LM is the dermatological finding of multiple pleomorphic round-to-oval papules, papulopustules or nodules with ulceration and brown lamellar crusted lesions disseminated over the trunk and extremities. These skin lesions may be preceded by fever, malaise, myalgia, headache and weight changes over 4 weeks prior to the appearance of skin lesions. A biopsy is recommended.
and is useful in excluding other causes such as bacterial, fungal and mycobacterial infections. Microscopic evaluation may reveal nonspecific findings such as perivascular congestion along with dermal infiltrate composed of plasma cells. Most reports show limited or no spirochetes.\textsuperscript{6,15,16} It is acknowledged that immunohistochemistry is superior in detecting spirochetes in comparison with the silver stains.\textsuperscript{16,17} However, this immunohistochemistry may not always be available on a routine basis at many laboratories. Thus, clinical pathologic correlation with serologic testing is key to prompt diagnosis and treatment of secondary syphilis.

Successful treatment with aqueous crystalline penicillin G has been reported, with regimens varying from single intramuscular injection, three weekly injections and 14 days of parenteral penicillin.\textsuperscript{1,7,10,12} Clinicians must stay vigilant for possible Jarisch–Herxheimer reaction, and HIV-infected patients on ART should continue antiretrovirals.\textsuperscript{18} Lesions respond to therapy leaving minimal residual effects.\textsuperscript{10,18}

**Conclusion**

With its multiple stages and wide clinical presentation, syphilis has been described as the great imposter. LM can be mistaken for a disseminated mycosis or mycobacterial disease. Our patient with well-controlled HIV infection was diagnosed with LM based on clinical suspicion, risk factors and serologic testing. This rare case also highlights that LM can occur in patients with HIV outside the clinical spectrum of IRIS and without profound immunosuppression. Of significance, the United States has seen an increase in reported syphilis cases, with the highest rate occurring among MSM.\textsuperscript{9} The risk behaviors associated with acquiring syphilis also increase the likelihood of acquiring HIV.\textsuperscript{19} More than half of newly diagnosed HIV infections in the United States are MSM.\textsuperscript{8} Likewise, more than 50% of MSM with syphilis are also co-infected with HIV.\textsuperscript{9} With these two coexistent epidemics, clinicians must be vigilant of this rare manifestation of a common condition, especially among MSM. Clinical suspicion combined with serologic testing for syphilis is key for early diagnosis and treatment.

**Declaration of conflicting interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**

The author(s) received no financial support for the research, authorship, and/or publication of this article.

**Informed consent**

Written informed consent was obtained from the patient(s) for their anonymized information to be published in this article.

**References**

1. Pföhler C, Koerner R, von Muller L, et al. Lues maligna in a patient with unknown HIV infection. BMJ Case Reports 2011; 2011: bcr0520114221.
2. Cripps DJ and McDonald R. Syphilis maligna praecox—the first patient seen at MGH in 1821. N Engl J Med 1977; 296: 695.
3. Haslund A. Syphilis maligna. Arch Fur Dermatologie Syph 1897; 38: 345–392.
4. Neisser A. Malignant syphilis. Br J Dermatol 1897; 9: 11–26.
5. Fisher DA. Lues maligna. Arch Dermatol 1969; 99: 70.
6. D’Amico R and Zalusky R. A case of lues maligna in a patient with acquired immunodeficiency syndrome (AIDS). Scand J Infect Dis 2005; 37: 697–700.
7. Sands M and Markus A. Lues maligna, or ulceronodular syphilis, in a man infected with human immunodeficiency virus: case report and review. Clin Infect Dis 1995; 20: 387–390.
8. Centers for Disease Control Prevention. Diagnoses of HIV infection in the United States and dependent areas, 2014. HIVSurvRep 2015; 26: 1–123.
9. Workowski KA. Centers for disease control and prevention sexually transmitted diseases treatment guidelines. Clin Infect Dis 2015; 61(Suppl. 8): S759–S762.
10. Tucker JD, Shah S, Jarell AD, et al. Lues maligna in early HIV infection case report and review of the literature. Sex Transm Dis 2009; 36: 512–514.
11. Corti M, Solari R, De Carolis L, et al. Malignant syphilis in a patient infected by human immunodeficiency virus. Case report and literature review. Rev Chilena Infectol 2012; 29: 678–681.
12. Alves J, António AM, Matos D, et al. Malignant lues in an immunocompetent patient. Int J STD AIDS 2015; 26: 518–520.
13. Hofmann UB, Hund M, Brocker E-B, et al. “Lues maligna” bei insulinpflichtigem Diabetes mellitus [“Lues Maligna” in a Female Patient with Diabetes]. J Der Disch Dermatologischen Gesellschaft 2005; 3: 780–782.
14. Martin-Blondel G, Mars LT and Liblau RS. Pathogenesis of the immune reconstitution inflammatory syndrome in HIV-infected patients. Curr Opin Infect Dis 2012; 25: 312–320.
15. Liotta EA, Turiansky GW, Schold JD, et al. Secondary syphilis in 2 HIV-1 positive patients. Cutis 2000; 66: 383–386, 389.
16. Hoang MP, High WA and Molberg KH. Secondary syphilis: a histologic and immunohistochemical evaluation. J Cutan Pathol 2004; 31: 595–599.
17. Rosa G, Procop GW, Schold JD, et al. Secondary syphilis in HIV positive individuals: correlation with histopathologic findings, CD4 counts, and quantity of treponemes in microscopic sections. J Cutan Pathol 2016; 43: 847–851.
18. Gevorgyan O, Owen BD, Balavenkataraman A, et al. A nodular-ulcerative form of secondary syphilis in AIDS. Proc (Bayl Univ Med Cent) 2017; 30: 80–82.
19. Centers for Disease Control Prevention (CDC). Notes from the field: repeat syphilis infection and HIV coinfection among men who have sex with men—Baltimore, Maryland, 2010–2011. MMWR Morb Mortal Wkly Rep 2013; 62: 649–650.